Skip to main content
Fig. 5 | BMC Rheumatology

Fig. 5

From: Serum protein biomarkers for juvenile dermatomyositis: a pilot study

Fig. 5

Examples of JDM serum protein biomarkers and their response to medical therapy. The upper panel shows biomarkers that normalized after treatment C-X-C motif chemokine 10 (IP-10) and C-X-C motif chemokine 11 (I-TAC). The middle panel shows fibrinogen and Vascular cell adhesion protein 1 (VCAM-1) decreased from untreated active levels before and while tapering therapy, when they appeared to be clinically inactive, and rebounded after tapering therapy. The lower panel shows biomarkers that did not respond to treatment: Growth/differentiation factor 9 (GDF-9) and Interleukin-10 receptor subunit alpha (IL10 -Ra). Symbols indicate the combination therapies for each patient: A, B, D. ▲ A, B, D, G. ■ A, B, E, F. * B, D. ∆ B, D, F. ♦B, D, G. οB, F. A = IV Solumedrol, B = oral prednisone; D = methotrexate; E = cyclosporine; F = mycophenolate mofetil; G = hydroxychloroquine. MSA profile for each patient is indicated in the insert in the figure

Back to article page